The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMediumUpdated•Originally published 24 February 2026•Updated 24 February 2026•

1 min read

Beam Therapeutics Reports Massive Revenue Beat and Narrower Q4 Loss

Key Facts

1Beam Therapeutics reported a loss of $0.1 per share, significantly beating the consensus estimate of a $1.13 loss.

3 months ago

Version History

Version 13 months ago

What changed: Updated the story to include specific revenue figures showing a massive beat against expectations and incorporated the revised consensus EPS estimate from Benzinga.

Beam Therapeutics reported its fourth-quarter financial results, posting a loss of $0.10 per share, which significantly outperformed analyst consensus estimates ranging from $0.99 to $1.13 per share. The company's revenue reached a staggering $114.11 million for the quarter, massively exceeding the market estimate of $12.567 million. This performance marks a substantial year-over-year improvement from the $1.09 per share loss reported in the same period last year. The massive beat on both revenue and earnings per share (EPS) is viewed as a strong positive catalyst for the biotech firm's stock. Investors are reacting favorably to the company's ability to drive exponential revenue growth while maintaining operational efficiency. This financial update reinforces confidence in the company's gene-editing platform and its path toward fiscal stability.